Comment on "SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis" critical considerations on biomarker validation and Supraphysiological drug concentrations. [PDF]
J Transl MedChen J, Yan L.
europepmc +1 more source
Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes. [PDF]
CureusKhanna S, Malik M, Ahmad R.
europepmc +1 more source
Authors' Response to "Comment on 'SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis'". [PDF]
J Transl MedRostami-Afshari B +3 more
europepmc +1 more source
Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats. [PDF]
Sci RepSedik AA +3 more
europepmc +1 more source
Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]
CureusPrakash V, Goel N.
europepmc +1 more source
Surfing the vildagliptin tsunami
Indian Journal of Endocrinology and Metabolism, 2020 openaire +3 more sources
Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets. [PDF]
J Comput Aided Mol DesInglot TW.
europepmc +1 more source
A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.
Indian J PharmacolShahi MK +4 more
europepmc +1 more source
Unusual Presentation of Bullous Pemphigoid as Erythroderma in an Elderly Male. [PDF]
Indian Dermatol Online JThind A, Stephen, Singh A, Kaur S.
europepmc +1 more source
SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]
J Diabetes ResAlfonso Arvez MJ +4 more
europepmc +1 more source